Jolie Gan
34 followers · 22 following · 2852 views
on the atlas · 56
- The Painted Protest, by Dean Kissick3 savers
- Harry Frankfurt's "On Bullshit"1 savers
- ‘Red Pocket’ by Austin Chen | Frieze1 savers
- What I did wrong with Artemis - by Alex Shintaro Araki1 savers
- a gen z guide to fixing your doom-pilled brain3 savers
- Thoughts — Celine Halioua1 savers
- Can Tech Startups Do Journalism? - The Ringer2 savers
- Jann Wenner1 savers
- S.I. Newhouse Jr., Who Turned Condé Nast Into a Magazine Powerhouse, Dies at 89 - The New York Times1 savers
- How Nature Became a 'Prestige' Journal - Asimov Press1 savers
- A History of Scientific Journals | UCL Press1 savers
- 2025 letter | Dan Wang62 savers
- Navigating the unpredictability of everything2 savers
- Is Ockham’s razor losing its edge? New perspectives on the principle of model parsimony | PNAS1 savers
- Frank H. Netter - Wikipedia1 savers
- Why science needs outsiders - Works in Progress Magazine2 savers
- File:Cabinet of Curiosities 1690s Domenico Remps.jpg - Wikimedia Commons1 savers
- Science and Culture: “The Best That Has Been Thought and Said” - Elicit1 savers
- Finalists 2025 | Royal Society1 savers
- Entangled Life - Wikipedia1 savers
- Dead to Rights (film) - Wikipedia1 savers
- The Pour-igin of Species2 savers
- Allen Institute for AI2 savers
- About – Medra3 savers
- V&A - Vivienne Westwood - Early years1 savers
- To Scale: TIME - YouTube2 savers
- Discovering Literature: articles and resources – British Library1 savers
- Dan Wang | The secure transport of light15 savers
- Stelarc - Wikipedia1 savers
- The Price of Progress: What Tokyo Looks Like at 8AM - YouTube1 savers
- Opinion | Elite Colleges Have Found a New Virtue for Applicants to Fake - The New York Times1 savers
- Make Something Heavy - by Anu - Working Theorys17 savers
- Nobel disease - Wikipedia3 savers
- The rise and fall of the industrial R&D lab - Works in Progress5 savers
- How to Do Great Work69 savers
- How I've run major projects | benkuhn.net53 savers
- I should have loved biology36 savers
- no exit - by Ava - bookbear express23 savers
- Chloe's Garden22 savers
- Work on these things21 savers
- The Load-Bearing Relationship17 savers
- advice16 savers
- Advice For New College Grads14 savers
- San Francisco, I love you?13 savers
- Find Your People - Jessica Livingston12 savers
- Career advice | What's new12 savers
- The pharma industry from Paul Janssen to today: why drugs got harder to develop and what we can do about it | Alex’s blog10 savers
- What to learn10 savers
- 10 things I wish I knew about careers when I started10 savers
- Leverage Points: Places to Intervene in a System - The Donella Meadows Project9 savers
- Notes on China - by Dwarkesh Patel - Dwarkesh Podcast9 savers
- I Was An MIT Educated Neurosurgeon Now I'm Unemployed And Alone In The Mountains How Did I Get Here? - YouTube6 savers
- Can AI Scaling Continue Through 2030? | Epoch AI6 savers
- Knightian uncertainty5 savers
- AI Slop Is Killing Our Channel - YouTube2 savers
- Cosmik2 savers
highlights · 186
Few biotechnology companies are led by young founders, and fewer by female founders.
Thoughts — Celine HaliouaUpdate on this - I’ve become pretty bearish on academic scientific founders. I’m more interested now in the idea of non-scientific founders building bio companies…
Thoughts — Celine HaliouaIn September 2017, Wenner Media announced that the remaining 51% of Rolling Stone was up for sale
Jann WennerWenner's interview with Bono received a National Magazine Award nomination.
Jann WennerHe also discovered photographer Annie Leibovitz when she was a 21-year-old San Francisco Art Institute student.
Jann WennerBut when Mr. Newhouse deemed a magazine’s direction “screwy,” he didn’t hesitate to fire editors, sometimes so maladroitly that they first found out about their dismissals on television or in the gossip columns.
S.I. Newhouse Jr., Who Turned Condé Nast Into a Magazine Powerhouse, Dies at 89 - The New York Times“I am not an editor,” Mr. Newhouse told The New York Times in 1989. “I flounder when people ask me, ‘What would you do?’ ” His philosophy, he said, was to let his editors run free. “We feel almost that whichever way it goes, as long as it doesn’t do something absolutely screwy, you can build a magazine around the direction an editor takes.”
S.I. Newhouse Jr., Who Turned Condé Nast Into a Magazine Powerhouse, Dies at 89 - The New York TimesHuxley also encouraged other prominent figures to contribute, even though they generally preferred to publish lengthy scientific essays in more established monthly periodicals.
How Nature Became a 'Prestige' Journal - Asimov PressHuxley, alarmed by scientific errors in popular books and frustrated by theological overtones he believed many journalists (particularly women) wove into their writing, concluded that only researchers themselves could properly educate the public.
How Nature Became a 'Prestige' Journal - Asimov PressIt’s never worth forgetting that at the dawn of the Cold War, the US deported Qian Xuesen, the CalTech professor who then built missile delivery systems for Beijing. Or these Chinese researchers expect life in Shanghai to be safer or more fun than in San Francisco. Or they miss mom. People move for all sorts of reasons, so I’m reluctant to believe that the US has a durable talent advantage.
2025 letter | Dan WangBeijing has coveted Taiwan for approximately seven decades before people were talking about AI.
2025 letter | Dan WangI wonder whether this message is helping to endear his product to the public.
2025 letter | Dan WangThere’s a general lack of cultural awareness in the Bay Area. It’s easy to hear at these parties that a person’s favorite nonfiction book is Seeing Like a State while their aspirationally favorite novel is Middlemarch. Silicon Valley often speaks in strange tongues, starting podcasts and shows that are popular within the tech world but do not travel far beyond the Bay Area. Though San Francisco has produced so much wealth, it is a relative underperformer in the national culture.
2025 letter | Dan WangIn interviews, scientists described how challenging amyloid dogma caused their papers to be rejected, grant applications to be blocked, and speaking slots to be cancelled.
Why science needs outsiders - Works in Progress MagazineIt was selected as the Chinese entry for Best International Feature Film at the 98th Academy Awards.[5]
Dead to Rights (film) - Wikipedianever relinquished control of her company.
V&A - Vivienne Westwood - Early years'I didn't know how a working-class girl like me could possibly make a living in the art world'
V&A - Vivienne Westwood - Early yearsI cooked a lot of fish as I wrote, in the Cantonese style: steaming a whole bronzino or a filet of sea trout for ten minutes, then drizzled with ginger, spring onion, soy sauce, and sizzling olive oil.
Dan Wang | The secure transport of lightBut in the college process, you can gamify almost anything. Students, as ever, will find ways to hack the system. And the fortunate ones won’t have to do it alone: They’ll have online guides, school counselors and private tutors to help them learn to simulate earnestness.
Opinion | Elite Colleges Have Found a New Virtue for Applicants to Fake - The New York TimesThis fall, an expanding number of top schools — including Columbia, M.I.T., Northwestern, Johns Hopkins, Vanderbilt and the University of Chicago — will begin accepting “dialogues” portfolios from Schoolhouse.world, a platform co-founded by Sal Khan, the founder of Khan Academy, to help students with math skills and SAT prep. High-schoolers will log into a Zoom call with other students and a peer tutor, debate topics like immigration or Israel-Palestine, and rate one another on traits like empathy, curiosity or kindness. The Schoolhouse.world site offers a scorecard: The more sessions you atte…
Opinion | Elite Colleges Have Found a New Virtue for Applicants to Fake - The New York TimesWe’re working towards unpacking the research process into smaller, composable and connected units that enable large-scale open collaboration. These include hypotheses, observations, connections, and reviews that all merit recognition.
Cosmikwhile scientific reception was highly polarized
The Mismeasure of Man - Wikipediaon how the rising costs of drug development had constrained his company and changed the nature of the industry. Such costs are a shame, he said:
The pharma industry from Paul Janssen to today: why drugs got harder to develop and what we can do about it | Alex’s blogplausibly too stringent for lethal diseases with few good options like pancreatic cancer, but may actually be too relaxed for conditions with good treatment options like diabetes.
The pharma industry from Paul Janssen to today: why drugs got harder to develop and what we can do about it | Alex’s blogadapts the standard of evidence required to incorporate the need for new treatments and the risk of exposing patients to ineffective, or harmful, drugs.
The pharma industry from Paul Janssen to today: why drugs got harder to develop and what we can do about it | Alex’s blogindustrialise this sort of phenotypic screening.
The pharma industry from Paul Janssen to today: why drugs got harder to develop and what we can do about it | Alex’s blogand do more phenotypic screens with a wider diversity of input molecules (including obscure natural products). Most approved small molecule drugs were actually discovered by phenotypic screens — like the one that Janssen used to find haloperidol.
The pharma industry from Paul Janssen to today: why drugs got harder to develop and what we can do about it | Alex’s blogOf the top 10 revenue drugs in 2022, 3 were monoclonal antibodies.
The pharma industry from Paul Janssen to today: why drugs got harder to develop and what we can do about it | Alex’s blogMonoclonal antibodies are similar to the antibodies your body produces in response to an infection, but intentionally raised against disease-relevant targets and produced in immortalised cell cultures.
The pharma industry from Paul Janssen to today: why drugs got harder to develop and what we can do about it | Alex’s blogUnlike small molecules, biologics are grown in living organisms, not chemically synthesised.
The pharma industry from Paul Janssen to today: why drugs got harder to develop and what we can do about it | Alex’s blogBiotech executives are incentivized to run trials of their compounds even if they can’t secure the funds to sufficiently enrol them, or if someone else is already testing a similar drug, as the alternative is giving up their job.
The pharma industry from Paul Janssen to today: why drugs got harder to develop and what we can do about it | Alex’s blogimplying 95% of the effort was unlikely to yield actionable information. Wasteful spending is a feature of the industry at large; take for example the estimated $1.6 billion spent on trials for 16 different IGF-1R inhibitors in cancer, none of which were approved
The pharma industry from Paul Janssen to today: why drugs got harder to develop and what we can do about it | Alex’s blogWhen drug developers can’t secure their target level of funding or patients for their trial they will often go ahead anyway, even though underfunded and under-enrolled trials lead to wasteful research.
The pharma industry from Paul Janssen to today: why drugs got harder to develop and what we can do about it | Alex’s blogManufacturing for drugs entering human trials are controlled by strict good manufacturing practice (GMP) regulations,
The pharma industry from Paul Janssen to today: why drugs got harder to develop and what we can do about it | Alex’s blogTrials now cost as much as $100,000 per patient to run, and sometimes up to $300,000 or even $500,000 per patient
The pharma industry from Paul Janssen to today: why drugs got harder to develop and what we can do about it | Alex’s blogn 2022, the industry spent around $200 billion on R&D, more than four times the US National Institute of Health’s (NIH) budget of $48 billion. Pharmaceuticals is the third most R&D intensive sector in the OECD countries.
The pharma industry from Paul Janssen to today: why drugs got harder to develop and what we can do about it | Alex’s blogBefore the 1950s regulation was embryonic: it focused on preventing the sale of fraudulent, impure, or adulterated goods, or was limited to specific diseases or products.
The pharma industry from Paul Janssen to today: why drugs got harder to develop and what we can do about it | Alex’s blogClinical trials are usually too small to pick up rare side effects, like the risk of blood clots (3.2 reported per million doses) that ultimately sank the Johnson & Johnson COVID-19 vaccine7,
The pharma industry from Paul Janssen to today: why drugs got harder to develop and what we can do about it | Alex’s blogNovo Nordisk developed an oral version of semaglutide by formulating the drug with a permeability enhancer called SNAC. SNAC carries the semaglutide peptide through the walls of the gut and eases its absorption into the bloodstream.
The pharma industry from Paul Janssen to today: why drugs got harder to develop and what we can do about it | Alex’s blogAs Janssen did with haloperidol, chemists make structural tweaks until they arrive at a satisfactory ‘lead candidate’ molecule.
The pharma industry from Paul Janssen to today: why drugs got harder to develop and what we can do about it | Alex’s blogcheck whether any of them stick to the target.
The pharma industry from Paul Janssen to today: why drugs got harder to develop and what we can do about it | Alex’s blogThe starting point for drug discovery is usually some sort of screen: running hundreds, thousands, or even millions of compounds through parallel (high-throughput) experiments to see which, if any, usefully affect a target of interest.
The pharma industry from Paul Janssen to today: why drugs got harder to develop and what we can do about it | Alex’s blogMost basic research takes place in academia,
The pharma industry from Paul Janssen to today: why drugs got harder to develop and what we can do about it | Alex’s blogIt would be effectively impossible to start a biotech company today with such a paltry sum. Yet, Janssen succeeded.
Convoke Raises $8.6M to Build the AI Operating System for Biopharma - Convoke | Biopharma's new workspaceRabe's appeals to the Japanese using his Nazi Party credentials often only delayed them, but the delay allowed hundreds of thousands of refugees to escape. The documentary Nanking credited Rabe with saving the lives of 250,000 Chinese civilians;
John RabeRabe and his zone administrators tried frantically to stop the atrocities
John RabeOn 1 March 1934 he joined the Nazi Party.[3]
John Rabealthough it is unknown whether Nobel Prize winners are more prone to this tendency than other individuals.[7]
Nobel disease - WikipediaWe have also learnt that it is still very hard to sell to industry the economic value of mathematical elegance.
E.W. Dijkstra Archive: Visuals for BP's Venture Research Conferencebelievers in the dominant hypothesis suppressed research on alternative ideas: They influenced what studies got published in top journals, which scientists got funded, who got tenure, and who got speaking slots at reputation-buffing scientific conferences. This . . . is a big reason why there is no treatment for Alzheimer’s.”
How to Improve Both Scientific Innovation and Reproducibility at Once – Good Science Project